BACKGROUND: The objective of the current study was to determine whether her-2 amplification was associated with a pathologic response to preoperative chemotherapy with taxanes in patients with early-stage breast carcinoma. METHODS: The authors evaluated 71 patients treated for AJCC Stage II and III breast carcinoma with preoperative taxanes whose tissue specimens were still available. Fifty-seven patients (80%) had received paclitaxel and 14 (20%) had received docetaxel (4 cycles of either drug). Amplification of the her-2 gene was determined using fluorescence in situ hybridization. RESULTS: The median patient age was 49 years (range, 21-70 years). Forty-eight patients (68%) had Stage II breast carcinoma and 23 (32%) had Stage III disease. her-2 gene amplification was detected in 19 tumor specimens (28%). Hormone receptors (estrogen and/or progesterone) were detected in 11 her-2-positive tumor specimens (58%) and in 31 her-2-negative tumor specimens (85%). Eight pathologic complete responses (pCR; breast and axillary lymph nodes) occurred, 3 (16%) in patients with her-2-positive tumor specimens and five (10%) in patients with her-2-negative tumor specimens (P = 0.68). Twelve patients achieved pCR in the breast, 5 (26%) in patients with her-2-positive tumors and 7 (15%) in patients with her-2-negative tumors (P = 0.3). At a median follow-up of 61 months, none of the patients with a pCR developed recurrent disease, regardless of their her-2 status. The progression-free and overall survival rates were similar in both HER-2-positive and her-2-negative groups (P = 0.45 and P = 0.14, respectively). CONCLUSIONS: her-2 gene amplification was not found to be predictive of a pathologic response to preoperative taxanes in patients with early-stage breast carcinoma. Copyright 2004 American Cancer Society.
BACKGROUND: The objective of the current study was to determine whether her-2 amplification was associated with a pathologic response to preoperative chemotherapy with taxanes in patients with early-stage breast carcinoma. METHODS: The authors evaluated 71 patients treated for AJCC Stage II and III breast carcinoma with preoperative taxanes whose tissue specimens were still available. Fifty-seven patients (80%) had received paclitaxel and 14 (20%) had received docetaxel (4 cycles of either drug). Amplification of the her-2 gene was determined using fluorescence in situ hybridization. RESULTS: The median patient age was 49 years (range, 21-70 years). Forty-eight patients (68%) had Stage II breast carcinoma and 23 (32%) had Stage III disease. her-2 gene amplification was detected in 19 tumor specimens (28%). Hormone receptors (estrogen and/or progesterone) were detected in 11 her-2-positive tumor specimens (58%) and in 31 her-2-negative tumor specimens (85%). Eight pathologic complete responses (pCR; breast and axillary lymph nodes) occurred, 3 (16%) in patients with her-2-positive tumor specimens and five (10%) in patients with her-2-negative tumor specimens (P = 0.68). Twelve patients achieved pCR in the breast, 5 (26%) in patients with her-2-positive tumors and 7 (15%) in patients with her-2-negative tumors (P = 0.3). At a median follow-up of 61 months, none of the patients with a pCR developed recurrent disease, regardless of their her-2 status. The progression-free and overall survival rates were similar in both HER-2-positive and her-2-negative groups (P = 0.45 and P = 0.14, respectively). CONCLUSIONS:her-2 gene amplification was not found to be predictive of a pathologic response to preoperative taxanes in patients with early-stage breast carcinoma. Copyright 2004 American Cancer Society.
Authors: David Muñoz-Gonzalez; Isabel Zeichner-Gancz; Myrna Candelaria; Maria Teresa Ramirez-Ugalde; Manuel Perez-Sanchez; Guadalupe Cervantes-Vazquez; David Cantu-de Leon; Arcelia Mora-Tizcareño; Julio Leonor-Ortíz Journal: Med Oncol Date: 2005 Impact factor: 3.064
Authors: Francisco J Esteva; Carol D Cheli; Herbert Fritsche; Monica Fornier; Dennis Slamon; Robert P Thiel; Diana Luftner; Farooq Ghani Journal: Breast Cancer Res Date: 2005-04-08 Impact factor: 6.466
Authors: A K Koutras; K T Kalogeras; M-A Dimopoulos; R M Wirtz; U Dafni; E Briasoulis; D Pectasides; H Gogas; C Christodoulou; G Aravantinos; G Zografos; E Timotheadou; P Papakostas; H Linardou; E Razis; T Economopoulos; H P Kalofonos; G Fountzilas Journal: Br J Cancer Date: 2008-11-04 Impact factor: 7.640
Authors: Miguel Martín; Aleix Prat; Alvaro Rodríguez-Lescure; Rosalía Caballero; Mark T W Ebbert; Blanca Munárriz; Manuel Ruiz-Borrego; Roy R L Bastien; Carmen Crespo; Carole Davis; César A Rodríguez; José M López-Vega; Vicente Furió; Ana M García; Maribel Casas; Matthew J Ellis; Donald A Berry; Brandelyn N Pitcher; Lyndsay Harris; Amparo Ruiz; Eric Winer; Clifford Hudis; Inge J Stijleman; David P Tuck; Eva Carrasco; Charles M Perou; Philip S Bernard Journal: Breast Cancer Res Treat Date: 2013-02-20 Impact factor: 4.872
Authors: Yun Lu; Meng Li; Adriana V F Massicano; Patrick N Song; Ameer Mansur; Katherine A Heinzman; Benjamin M Larimer; Suzanne E Lapi; Anna G Sorace Journal: Molecules Date: 2021-03-12 Impact factor: 4.411